+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety and effects of marstacimab, a study medicine, for treating hemophilia in male pediatric patients aged 1 to 17 years. The study focuses on severe Hemophilia A and moderately severe to severe Hemophilia B, including participants with or without inhibitors. Enrollment is done sequentially by age groups starting with adolescents, then children aged 6 to 11 years, followed by children aged 1 to 5 years. All participants will receive weekly subcutaneous injections of marstacimab, initially administered at the study site with subsequent doses given either at home or at the study site over a 12-month treatment period. The study compares participants experiences during treatment to their historical bleeding and treatment records to assess how marstacimab may help prevent bleeding episodes common in hemophilia. Participants will be involved for about 14 months, including a screening period of roughly one month, 12 months of treatment, and a one-month follow-up. They will attend at least 10 study visits, with the option of completing two visits at home if regulations allow, and receive six scheduled phone calls approximately every two months. Researchers will monitor bleeding rates, safety events, immune responses, joint health, and quality of life during this time.

Age: 1Year - 17YearsMALEPhase 3
63 locations
O

Actively Recruiting

Researchers are evaluating the effect of nipocalimab on total serum immunoglobulin G IgG in children and adolescents aged 2 to less than 18 years with generalized myasthenia gravis gMG who have an insufficient response to stable standard therapy. The study also assesses the safety, tolerability, and pharmacokinetics of nipocalimab in this pediatric population. Participants are grouped by age into children 2 to less than 12 years and adolescents 12 to less than 18 years. Participants receive nipocalimab as an intravenous infusion once every two weeks for 24 weeks. After this treatment period, they have the option to join a long-term extension phase. The study is open-label and uncontrolled, focusing on assessing pharmacokinetics, pharmacodynamics, safety, and activity of nipocalimab in children and adolescents with gMG. Throughout the study, participants undergo monitoring for changes in serum IgG levels and evaluations of adverse events, laboratory tests, vital signs, and physical examinations up to three years. Researchers also assess neurological function and quality of life measures using standardized tools. Blood samples are collected to evaluate drug concentration and immune response. Safety and tolerability are closely monitored during and after treatment, with the entire participation lasting up to three years.

Age: 2Years - 17YearsAll GendersPhase 2Phase 3
19 locations
R

Actively Recruiting

Researchers are evaluating the effects of teplizumab compared with a placebo in individuals aged 1 to 25 years who have recently been diagnosed with Stage 3 type 1 diabetes. This Phase 3, multicenter, randomized, double-blind study aims to measure changes in blood sugar control and the ability to reduce prandial insulin use over 52 weeks. Both groups will continue their standard insulin therapy during the study. Participants will receive either teplizumab or a matching placebo through intravenous infusions, with teplizumab doses gradually increasing. The study includes two groups one receiving the study drug and the other receiving placebo infusions. The total study period for each participant lasts about 84 weeks 19 months, during which participants are closely monitored. Throughout the study, participants will be regularly evaluated for blood sugar levels, insulin use, and markers of diabetes control including glycated hemoglobin HbA1c, C-peptide levels, and glucose monitoring. Safety will be assessed by tracking adverse events and immune responses. The research team will monitor participants at specified intervals up to 78 weeks to assess treatment effects and safety.

Age: 1Year - 25YearsAll GendersPhase 3
202 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
S

Actively Recruiting

This research evaluates the effects of the Close Collaboration with Parents, a family-centered care approach for neonatal intensive care unit NICU staff, on parents of newborns in the NICU. The study compares experiences before and after this intervention, focusing on family-centered care quality as rated by parents, parental anxiety symptoms, and readiness for the infants discharge. The intervention is planned to be implemented from December 2023 through December 2024. The Close Collaboration with Parents intervention educates NICU healthcare staff to better observe infants individual needs, support parents in understanding and participating in their infants care, and involve parents in decision-making from early care through discharge preparation. Data will be collected during three phases before the intervention September to December 2023, during the intervention January to December 2024, and after January to April 2025. Parents and newborns admitted before and after the intervention form two groups for comparison. Participants will be parents of infants admitted to the NICU for at least two weeks. Researchers will collect data on family-centered care quality, parental anxiety, and discharge readiness around the infants discharge at about one month of age. Data will be pseudonymized and securely managed, with statistical analyses adjusting for factors like length of stay and parental mental health history. Participation spans from pre-intervention data collection through post-intervention follow-up, lasting over a year.

All AgesAll Genders
1 location
M

Actively Recruiting

This research aims to create a detailed registry called the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions MINI minimum dataset. It focuses on outcomes and practices for infants born extremely prematurely at 22 to 23 weeks gestation and admitted to intensive care at participating hospitals. The goal is to improve understanding of treatments and outcomes in this vulnerable population. The study collects observational baseline data about both mothers and infants. This includes demographics, mothers health and delivery details, as well as the infants health, medical interventions, and clinical outcomes during neonatal intensive care. Participating centers may also optionally include data on infants born before 22 weeks gestation admitted to NICU. The collected data help hospitals with quality improvement, evaluate treatment-outcome associations, and monitor trends in neonatal care. Participants information is gathered as part of routine care from birth through intensive care admission and early life, up to 1 year old. Researchers compile a longitudinal database with uniform collection of characteristics and outcomes for all extremely premature births and admissions. This ongoing registry supports reporting, analysis, and tracking of neonatal-perinatal interventions and their results through January 2028 and study completion in 2030.

Age: 0Years - 1YearAll Genders
59 locations
O

Actively Recruiting

Researchers are studying long-term safety, tolerability, and effectiveness of marstacimab as a preventive treatment for severe hemophilia A and moderately severe to severe hemophilia B in participants who completed earlier Phase 3 studies without early termination. This open-label extension study involves male participants aged 1 to under 75 years with low coagulation factor activity, aiming to monitor marstacimabs impact over an extended period. Participants aged 12 years and older receive a 300 mg subcutaneous loading dose of marstacimab followed by 150 mg weekly injections, with dose escalation to 300 mg weekly if needed. Those aged 6 to under 12 years get an initial 150 mg loading dose followed by 75 mg weekly, with possible escalation to 150 mg weekly. All participants use a prefilled pen for administration, with a prefilled syringe available if needed or in regions where it is the commercial presentation. During the study, participants will be monitored for adverse events, serious adverse events, thrombotic events, injection site reactions, and laboratory changes over up to seven years. Researchers will also assess bleeding episodes, joint health, quality of life questionnaires, and coagulation factor consumption. Regular visits and evaluations will support long-term safety and efficacy monitoring throughout the study duration.

Age: 1Year - 74YearsMALEPhase 3
78 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations